RT Book, Section A1 Nahata, Milap C. A1 Taketomo, Carol A2 DiPiro, Joseph T. A2 Yee, Gary C. A2 Posey, L. Michael A2 Haines, Stuart T. A2 Nolin, Thomas D. A2 Ellingrod, Vicki SR Print(0) ID 1182426938 T1 Pediatrics: General Topics in Pediatric Pharmacotherapy T2 Pharmacotherapy: A Pathophysiologic Approach, 11e YR 2020 FD 2020 PB McGraw-Hill Education PP New York, NY SN 9781260116816 LK accesspharmacy.mhmedical.com/content.aspx?aid=1182426938 RD 2024/04/19 AB KEY CONCEPTS Children are not just “little adults,” and lack of data on important pharmacokinetic and pharmacodynamic differences has led to several disastrous situations in pediatric care. Variations in absorption of medications from the gastrointestinal tract, intramuscular injection sites, and skin are important in pediatric patients, especially in premature and other newborn infants. The rate and extent of organ function development and the distribution, metabolism, and elimination of drugs differ not only between pediatric versus adult patients but also among pediatric age groups. The effectiveness and safety of drugs may vary among age groups and from one drug to another in pediatric versus adult patients. Concomitant diseases may influence dosage requirements to achieve a targeted effect for a specific disease in children. Use of weight-based dosing of medications for obese children may result in suboptimal drug therapy. The myth that neonates and young infants do not experience pain has led to inadequate pain management in this pediatric population. Special methods of drug administration are needed for infants and young children. Many medicines needed for pediatric patients are not available in appropriate dosage forms; thus, the dosage forms of drugs marketed for adults may require modification for use in infants and children, necessitating assurance of potency and safety of drug use. The pediatric medication-use process is complex and error prone because of the multiple steps required in calculating, verifying, preparing, and administering doses.